Top

BMC Cancer

Published in:

Open Access 01-12-2020 | Colon Cancer | Research article

Establishment of an immune-related gene pair model to predict colon adenocarcinoma prognosis

Authors: Jihang Luo, Puyu Liu, Leibo Wang, Yi Huang, Yuanyan Wang, Wenjing Geng, Duo Chen, Yuju Bai, Ze Yang

Published in: BMC Cancer | Issue 1/2020

Abstract

Background

Colon cancer is the most common type of gastrointestinal cancer and has high morbidity and mortality. Colon adenocarcinoma (COAD) is the main pathological type of colon cancer, and much evidence has supported the correlation between the prognosis of COAD and the immune system. The current study aimed to develop a robust prognostic immune-related gene pair (IRGP) model to estimate the overall survival of patients with COAD.

Methods

The gene expression profiles and clinical information of patients with colon adenocarcinoma were obtained from the TCGA and GEO databases and were divided into training and validation cohorts. Immune genes were selected that showed a significant association with prognosis.

Results

Among 1647 immune genes, a model with 17 IRGPs was built that was significantly associated with OS in the training cohort. In the training and validation datasets, the IRGP model divided patients into the high-risk group and low-risk group, and the prognosis of the high-risk group was significantly worse (P<0.001). Univariate and multivariate Cox proportional hazard analyses confirmed the feasibility of this model. Functional analysis confirmed that multiple tumor progression and stem cell growth-related pathways were upregulated in the high-risk groups. Regulatory T cells and macrophages M0 were significantly highly expressed in the high-risk group.

Conclusion

We successfully constructed an IRGP model that can predict the prognosis of COAD, providing new insights into the treatment strategy of COAD.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/caac.21551.CrossRefPubMed

Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59(6):366–78. https://doi.org/10.3322/caac.20038.CrossRefPubMed

Bertelsen CA, Larsen HM, Neuenschwander AU, Laurberg S, Kristensen B, Emmertsen KJ. Long-term functional outcome after right-sided complete Mesocolic excision compared with conventional Colon Cancer surgery: a population-based questionnaire study. Dis Colon Rectum. 2018;61(9):1063–72. https://doi.org/10.1097/DCR.0000000000001154.CrossRefPubMed

Brungs D, Aghmesheh M, de Souza P, Carolan M, Clingan P, Rose J, et al. Safety and efficacy of Oxaliplatin doublet adjuvant chemotherapy in elderly patients with stage III Colon Cancer. Clin Colorectal Cancer. 2018;17(3):e549–e55. https://doi.org/10.1016/j.clcc.2018.05.004.CrossRefPubMed

Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, et al. Duration of adjuvant chemotherapy for stage III Colon Cancer. N Engl J Med. 2018;378(13):1177–88. https://doi.org/10.1056/NEJMoa1713709.CrossRefPubMedPubMedCentral

Guo M, Xu E, Ai D. Inferring bacterial infiltration in primary colorectal tumors from host whole genome sequencing data. Front Genet. 2019;10:213. https://doi.org/10.3389/fgene.2019.00213.CrossRefPubMedPubMedCentral

Okugawa Y, Grady WM, Goel A. Epigenetic alterations in colorectal Cancer: emerging biomarkers. Gastroenterology. 2015;149(5):1204–25 e12. https://doi.org/10.1053/j.gastro.2015.07.011.CrossRefPubMed

Allen J, Sears CL. Impact of the gut microbiome on the genome and epigenome of colon epithelial cells: contributions to colorectal cancer development. Genome Med. 2019;11(1):11. https://doi.org/10.1186/s13073-019-0621-2.CrossRefPubMedPubMedCentral

10.

Vasaikar S, Huang C, Wang X, Petyuk VA, Savage SR, Wen B, et al. Proteogenomic analysis of human Colon Cancer reveals new therapeutic opportunities. Cell. 2019;177(4):1035–49 e19. https://doi.org/10.1016/j.cell.2019.03.030.CrossRefPubMedPubMedCentral

11.

Choi MR, Gwak M, Yoo NJ, Lee SH. Regional Bias of Intratumoral genetic heterogeneity of apoptosis-related genes BAX, APAF1, and FLASH in Colon cancers with high microsatellite instability. Dig Dis Sci. 2015;60(6):1674–9. https://doi.org/10.1007/s10620-014-3499-2.CrossRefPubMed

12.

Sugai T, Eizuka M, Takahashi Y, Fukagawa T, Habano W, Yamamoto E, et al. Molecular subtypes of colorectal cancers determined by PCR-based analysis. Cancer Sci. 2017;108(3):427–34. https://doi.org/10.1111/cas.13164.CrossRefPubMedPubMedCentral

13.

Mamlouk S, Childs LH, Aust D, Heim D, Melching F, Oliveira C, et al. DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer. Nat Commun. 2017;8:14093. https://doi.org/10.1038/ncomms14093.CrossRefPubMedPubMedCentral

14.

Hsu YL, Lin CC, Jiang JK, Lin HH, Lan YT, Wang HS, et al. Clinicopathological and molecular differences in colorectal cancer according to location. Int J Biol Markers. 2019;34(1):47–53. https://doi.org/10.1177/1724600818807164.CrossRefPubMed

15.

Liu T, Li C, Jin L, Li C, Wang L. The Prognostic Value of m6A RNA Methylation Regulators in Colon Adenocarcinoma. Med Sci Monit. 2019;25:9435–45. https://doi.org/10.12659/MSM.920381.CrossRefPubMedPubMedCentral

16.

Missiaglia E, Jacobs B, D'Ario G, Di Narzo AF, Soneson C, Budinska E, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014;25(10):1995–2001. https://doi.org/10.1093/annonc/mdu275.CrossRefPubMed

17.

Patel SA, Minn AJ. Combination Cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity. 2018;48(3):417–33. https://doi.org/10.1016/j.immuni.2018.03.007.CrossRefPubMedPubMedCentral

18.

Woo SR, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annu Rev Immunol. 2015;33:445–74. https://doi.org/10.1146/annurev-immunol-032414-112043.CrossRefPubMed

19.

Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–45. https://doi.org/10.1038/nm.3909.CrossRefPubMedPubMedCentral

20.

Salem M, Wallace C, Velegraki M, Li A, Ansa-Addo E, Metelli A, et al. GARP dampens Cancer immunity by sustaining function and accumulation of regulatory T cells in the Colon. Cancer Res. 2019;79(6):1178–90. https://doi.org/10.1158/0008-5472.CAN-18-2623.CrossRefPubMedPubMedCentral

21.

Heinaniemi M, Nykter M, Kramer R, Wienecke-Baldacchino A, Sinkkonen L, Zhou JX, et al. Gene-pair expression signatures reveal lineage control. Nat Methods. 2013;10(6):577–83. https://doi.org/10.1038/nmeth.2445.CrossRefPubMedPubMedCentral

22.

Li B, Cui Y, Diehn M, Li R. Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung Cancer. JAMA Oncol. 2017;3(11):1529–37. https://doi.org/10.1001/jamaoncol.2017.1609.CrossRefPubMedPubMedCentral

23.

Wei HT, Guo EN, Liao XW, Chen LS, Wang JL, Ni M, et al. Genomescale analysis to identify potential prognostic microRNA biomarkers for predicting overall survival in patients with colon adenocarcinoma. Oncol Rep. 2018;40(4):1947–58. https://doi.org/10.3892/or.2018.6607.CrossRefPubMedPubMedCentral

24.

Marisa L, de Reynies A, Duval A, Selves J, Gaub MP, Vescovo L, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 2013;10(5):e1001453. https://doi.org/10.1371/journal.pmed.1001453.CrossRefPubMedPubMedCentral

25.

Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology. 2010;138(3):958–68. https://doi.org/10.1053/j.gastro.2009.11.005.CrossRefPubMed

26.

Cunningham F, Achuthan P, Akanni W, Allen J, Amode MR, Armean IM, et al. Ensembl 2019. Nucleic Acids Res. 2019;47(D1):D745–D51. https://doi.org/10.1093/nar/gky1113.CrossRefPubMed

27.

Liu W, Islamaj Dogan R, Kwon D, Marques H, Rinaldi F, Wilbur WJ, et al. BioC implementations in Go, Perl, Python and Ruby. Database (Oxford). 2014;2014. https://doi.org/10.1093/database/bau059.

28.

Bhattacharya S, Dunn P, Thomas CG, Smith B, Schaefer H, Chen J, et al. ImmPort, toward repurposing of open access immunological assay data for translational and clinical research. Sci Data. 2018;5:180015. https://doi.org/10.1038/sdata.2018.15.CrossRefPubMedPubMedCentral

29.

Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, et al. Orchestrating high-throughput genomic analysis with bioconductor. Nat Methods. 2015;12(2):115–21. https://doi.org/10.1038/nmeth.3252.CrossRefPubMedPubMedCentral

30.

Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–6. https://doi.org/10.1038/nm.3967.CrossRefPubMedPubMedCentral

31.

Wu M, Li X, Zhang T, Liu Z, Zhao Y. Identification of a nine-gene signature and establishment of a prognostic Nomogram predicting overall survival of pancreatic Cancer. Front Oncol. 2019;9:996. https://doi.org/10.3389/fonc.2019.00996.CrossRefPubMedPubMedCentral

32.

Wan B, Liu B, Huang Y, Yu G, Lv C. Prognostic value of immune-related genes in clear cell renal cell carcinoma. Aging (Albany NY). 2019;11(23):11474–89. https://doi.org/10.18632/aging.102548.CrossRef

33.

Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7. https://doi.org/10.1038/nmeth.3337.CrossRefPubMedPubMedCentral

34.

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50. https://doi.org/10.1073/pnas.0506580102.CrossRefPubMedPubMedCentral

35.

Domingues P, Gonzalez-Tablas M, Otero A, Pascual D, Miranda D, Ruiz L, et al. Tumor infiltrating immune cells in gliomas and meningiomas. Brain Behav Immun. 2016;53:1–15. https://doi.org/10.1016/j.bbi.2015.07.019.CrossRefPubMed

36.

Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz H-J, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. The Lancet Oncology. 2017;18(9):1182–91. https://doi.org/10.1016/s1470-2045(17)30422-9.CrossRefPubMedPubMedCentral

37.

Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26(4):566–76. https://doi.org/10.1038/s41591-020-0805-8.CrossRefPubMed

38.

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20. https://doi.org/10.1056/NEJMoa1500596.CrossRefPubMedPubMedCentral

39.

Le DT, Kim TW, Van Cutsem E, Geva R, Jager D, Hara H, et al. Phase II open-label study of Pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11–9. https://doi.org/10.1200/JCO.19.02107.CrossRefPubMed

40.

Eddy JA, Sung J, Geman D, Price ND. Relative expression analysis for molecular cancer diagnosis and prognosis. Technol Cancer Res Treat. 2010;9(2):149–59. https://doi.org/10.1177/153303461000900204.CrossRefPubMed

41.

Popovici V, Budinska E, Tejpar S, Weinrich S, Estrella H, Hodgson G, et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol. 2012;30(12):1288–95. https://doi.org/10.1200/JCO.2011.39.5814.CrossRefPubMed

42.

Ren L, Xu Y, Liu C, Wang S, Qin G. IL-17RB enhances thyroid cancer cell invasion and metastasis via ERK1/2 pathway-mediated MMP-9 expression. Mol Immunol. 2017;90:126–35. https://doi.org/10.1016/j.molimm.2017.06.034.CrossRefPubMed

43.

Lin S, Guo Q, Wen J, Li C, Lin J, Cui X, et al. Survival analyses correlate stanniocalcin 2 overexpression to poor prognosis of nasopharyngeal carcinomas. J Exp Clin Cancer Res. 2014;33:26. https://doi.org/10.1186/1756-9966-33-26.CrossRefPubMedPubMedCentral

44.

Krzystek-Korpacka M, Zawadzki M, Neubauer K, Bednarz-Misa I, Gorska S, Wisniewski J, et al. Elevated systemic interleukin-7 in patients with colorectal cancer and individuals at high risk of cancer: association with lymph node involvement and tumor location in the right colon. Cancer Immunol Immunother. 2017;66(2):171–9. https://doi.org/10.1007/s00262-016-1933-3.CrossRefPubMed

45.

Liu J, Wang D, Zhang C, Zhang Z, Chen X, Lian J, et al. Identification of liver metastasis-associated genes in human colon carcinoma by mRNA profiling. Chin J Cancer Res. 2018;30(6):633–46. https://doi.org/10.21147/j.issn.1000-9604.2018.06.08.CrossRefPubMedPubMedCentral

46.

Tell R, Rivera CA, Eskra J, Taglia LN, Blunier A, Wang QT, et al. Gastrin-releasing peptide signaling alters colon cancer invasiveness via heterochromatin protein 1Hsbeta. Am J Pathol. 2011;178(2):672–8. https://doi.org/10.1016/j.ajpath.2010.10.017.CrossRefPubMedPubMedCentral

47.

Najafi M, Farhood B, Mortezaee K. Contribution of regulatory T cells to cancer: a review. J Cell Physiol. 2019;234(6):7983–93. https://doi.org/10.1002/jcp.27553.CrossRefPubMed

48.

Liu X, Wu S, Yang Y, Zhao M, Zhu G, Hou Z. The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer. Biomed Pharmacother. 2017;95:55–61. https://doi.org/10.1016/j.biopha.2017.08.003.CrossRefPubMed

49.

Veglia F, Gabrilovich DI. Dendritic cells in cancer: the role revisited. Curr Opin Immunol. 2017;45:43–51. https://doi.org/10.1016/j.coi.2017.01.002.CrossRefPubMedPubMedCentral

50.

Giese MA, Hind LE, Huttenlocher A. Neutrophil plasticity in the tumor microenvironment. Blood. 2019;133(20):2159–67. https://doi.org/10.1182/blood-2018-11-844548.CrossRefPubMedPubMedCentral

51.

Olingy CE, Dinh HQ, Hedrick CC. Monocyte heterogeneity and functions in cancer. J Leukoc Biol. 2019;106(2):309–22. https://doi.org/10.1002/JLB.4RI0818-311R.CrossRefPubMed

52.

Reading JL, Galvez-Cancino F, Swanton C, Lladser A, Peggs KS, Quezada SA. The function and dysfunction of memory CD8(+) T cells in tumor immunity. Immunol Rev. 2018;283(1):194–212. https://doi.org/10.1111/imr.12657.CrossRefPubMed

53.

Townsend W, Pasikowska M, Yallop D, Phillips EH, Patten PEM, Salisbury JR, et al. The architecture of neoplastic follicles in follicular lymphoma; analysis of the relationship between the tumor and follicular helper T cells. Haematologica. 2020;105(6):1593–603. https://doi.org/10.3324/haematol.2019.220160.CrossRefPubMedPubMedCentral

54.

Taranger CK, Noer A, Sorensen AL, Hakelien AM, Boquest AC, Collas P. Induction of dedifferentiation, genomewide transcriptional programming, and epigenetic reprogramming by extracts of carcinoma and embryonic stem cells. Mol Biol Cell. 2005;16(12):5719–35. https://doi.org/10.1091/mbc.e05-06-0572.CrossRefPubMedPubMedCentral

55.

Hennigs A, Fuchs V, Sinn HP, Riedel F, Rauch G, Smetanay K, et al. Do patients after Reexcision due to involved or close margins have the same risk of local recurrence as those after one-step breast-conserving surgery? Ann Surg Oncol. 2016;23(6):1831–7. https://doi.org/10.1245/s10434-015-5067-1.CrossRefPubMed

56.

Anastassiou D, Rumjantseva V, Cheng W, Huang J, Canoll PD, Yamashiro DJ, et al. Human cancer cells express slug-based epithelial-mesenchymal transition gene expression signature obtained in vivo. BMC Cancer. 2011;11:529. https://doi.org/10.1186/1471-2407-11-529.CrossRefPubMedPubMedCentral

57.

Vecchi M, Nuciforo P, Romagnoli S, Confalonieri S, Pellegrini C, Serio G, et al. Gene expression analysis of early and advanced gastric cancers. Oncogene. 2007;26(29):4284–94. https://doi.org/10.1038/sj.onc.1210208.CrossRefPubMed

58.

Fu NY, Pal B, Chen Y, Jackling FC, Milevskiy M, Vaillant F, et al. Foxp1 is indispensable for ductal morphogenesis and controls the exit of mammary stem cells from quiescence. Dev Cell. 2018;47(5):629–44 e8. https://doi.org/10.1016/j.devcel.2018.10.001.CrossRefPubMed

59.

Wu J, Zhao Y, Zhang J, Wu Q, Wang W. Development and validation of an immune-related gene pairs signature in colorectal cancer. Oncoimmunology. 2019;8(7):1596715. https://doi.org/10.1080/2162402X.2019.1596715.CrossRefPubMedPubMedCentral

Title: Establishment of an immune-related gene pair model to predict colon adenocarcinoma prognosis
Authors: Jihang Luo
Puyu Liu
Leibo Wang
Yi Huang
Yuanyan Wang
Wenjing Geng
Duo Chen
Yuju Bai
Ze Yang
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Colon Cancer
Colon Cancer
Published in: BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-020-07532-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Detection of early adenocarcinoma of the esophagogastric junction by spraying an enzyme-activatable fluorescent probe targeting Dipeptidyl peptidase-IV

Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC)

Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation

Cancer staging in individuals with a severe psychiatric illness: a cross-sectional study using population-based cancer registry data

Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer